Novavax
NVAX
199 hedge funds and large institutions have $411M invested in Novavax in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 66 increasing their positions, 52 reducing their positions, and 51 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 52
6.1% more ownership
Funds ownership: 65.5% → 71.6% (+6.1%)
1% more call options, than puts
Call options by funds: $69.1M | Put options by funds: $68.2M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $448M → $411M (-$37.2M)
12% less funds holding
Funds holding: 225 → 199 (-26)
47% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$74.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$40.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.4M |
| 4 |
Coatue Management
New York
|
+$9.3M |
| 5 |
SCM
Shah Capital Management
Raleigh,
North Carolina
|
+$8.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$13.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.99M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.24M |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$3.8M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.5M |
NVAX Hedge Fund Activity: Q4 2023 in Review
199 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2023, worth a combined $411M — down 8.3% from $448M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of NVAX and 27 opened new positions — a net loss of 24 holders — while 52 trimmed existing stakes and 66 added.
The largest buyer was Morgan Stanley, adding an estimated $74.7M. The largest seller was Millennium Management, cutting an estimated $13.1M.
- 199 institutional investors held Novavax (NVAX) as of Q4 2023, down from 225 in Q3 2023.
- Funds reported $411M of Novavax stock for Q4 2023, down 8.3% quarter-over-quarter.
- 27 funds opened new Novavax positions in Q4 2023 and 51 closed out, a net change of -24 holders.
- The largest Novavax buyer in Q4 2023 was Morgan Stanley, an estimated $74.7M added.
- The largest Novavax seller in Q4 2023 was Millennium Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q4 2023.